Pacific Biosciences OF California, Inc. PACB
Biotechnology: Laboratory Analytical Instruments · IPO 2010 · data as of November 13, 2026
Pacific Biosciences OF California, Inc. (PACB) is a industrial company listed in the US with a market value of about $613M. In the twelve months to September 30, 2026 it had revenue of $161M and net income of -$131M, a net margin of -81.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 15% a year, a 5-year average ROIC of -169%.
About Pacific Biosciences OF California
Pacific Biosciences OF California is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2010. Revenue went from $61M in 2014 to $160M in 2025, growth of about 9.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 34% over three years (dilution for shareholders). It spends 61% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $161M | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M |
| Net income | -$131M | -$546M | -$310M | -$307M | -$314M | -$181M | $29M | -$84M | -$103M | -$92M | -$74M |
| Free cash flow | -$143M | -$114M | -$212M | -$268M | -$280M | -$117M | $18M | -$81M | -$68M | -$78M | -$76M |
| EPS (diluted) | $-0.42 | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | $-0.87 | $-0.83 |
| Net margin | -81.3% | -341.5% | -201.2% | -153.0% | -244.9% | -138.8% | 37.3% | -92.6% | -130.4% | -98.6% | -82.0% |
| ROIC | — | -701.3% | -70.5% | -43.4% | -20.3% | -8.0% | -21.9% | -68.0% | -44.8% | -71.1% | -55.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $2.74, 40% above the current price; targets range from $2.00 to $3.00; the consensus rating is “Buy”; expected EPS is $-0.49 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Pacific Biosciences OF California pay a dividend?
Not currently.
Is Pacific Biosciences OF California a good stock to buy?
We do not give buy or sell advice. Pacific Biosciences OF California scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.